Drug profile

The FDA adverse-event record for Omega-3 Fatty Acids

149 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Omega-3 Fatty Acids. See the species affected, top reactions, and outcomes below.

149
adverse-event reports
6.7%
death-coded share
Dog
most-reported species
24
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
149
Total Reports
10
Deaths Reported
6.7%
Death Rate

Active Ingredients

Omega-3 Fatty Acids

Administration Routes

UnknownOral

Species Affected

Dog 141
Cat 7
Human 1

Most Affected Breeds

Retriever - Labrador 21
Boxer (German Boxer) 9
Retriever - Golden 8
Terrier - Yorkshire 7
Maltese 6
Crossbred Canine/dog 6
Shepherd Dog - German 5
Terrier (unspecified) 5
Bichon Frise 4
Sheepdog - Shetland 4

Most Reported Reactions

Vomiting 24
Emesis 23
Diarrhoea 21
Lethargy (see also Central nervous system depression in 'Neurological') 19
Anorexia 15
Decreased appetite 15
Lack of efficacy - NOS 15
Elevated alanine aminotransferase (ALT) 11
Emesis (multiple) 9
Weight loss 9
Lethargy (see also Central nervous system depression in Neurological) 9
Other abnormal test result NOS 8

Outcome Breakdown

Recovered/Normal
54 (35.8%)
Ongoing
49 (32.5%)
Outcome Unknown
33 (21.9%)
Recovered with Sequela
5 (3.3%)
Died
5 (3.3%)
Euthanized
5 (3.3%)

Omega-3 Fatty Acids Adverse Event Insights

149 reports name Omega-3 Fatty Acids; 10 recorded a death outcome (6.7% of reported events, not a population-level mortality rate). Active ingredient: Omega-3 Fatty Acids. Administration routes: Unknown, Oral.

By species: Dog (141 reports), Cat (7 reports), Human (1 reports). By breed: Retriever - Labrador (21), Boxer (German Boxer) (9), Retriever - Golden (8).

Leading clinical signs: Vomiting (24), Emesis (23), Diarrhoea (21), Lethargy (see also Central nervous system depression in 'Neurological') (19). Outcome, 151 coded reports: Recovered/Normal leads at 35.8%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.